A Phase I Study of Relatlimab and BMS-986207 Immunotherapy plus Standard Treatment in People with Recurrent or Persistent Multiple Myeloma


Full Title

A Phase I/II Assessment of Combination Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 (BMS-986016) and Anti-TIGIT (BMS-986207)


The purpose of this study is to find the highest doses of the investigational drugs relatlimab and BMS-986207 when given alone and in combination with pomalidomide and dexamethasone in patients with multiple myeloma that has come back or continued to grow despite treatment. Pomalidomide and dexamethasone are standard drugs used to treat multiple myeloma.

On healthy immune cells, there are two proteins, LAG-3 and TIGIT, that help control how the immune system responds to an infection or cancer. In people with recurrent or persistent multiple myeloma, there is a higher number of these proteins on immune cells, which can help cancer hide from the immune system. Relatlimab blocks the LAG-3 protein and BMS-986207 blocks the TIGIT protein, which may help the immune system detect and destroy cancer cells.

Patients in this study will receive either relatlimab or BMS-986207 with pomalidomide and dexamethasone. Relatlimab and BMS-986207 are given intravenously (by vein) and pomalidomide and dexamethasone are taken orally (by mouth).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have multiple myeloma that has come back or continued to grow despite at least three prior regimens of treatment.
  • Patients should recover from the serious side effects of prior therapies before receiving the study treatment.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Alexander Lesokhin at 212-639-3069.





Disease Status

Relapsed or Refractory